RU2012115480A - РЕЖИМ ДОЗИРОВАНИЯ ПРИ ВВЕДЕНИИ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА EpCAMxCD3 - Google Patents
РЕЖИМ ДОЗИРОВАНИЯ ПРИ ВВЕДЕНИИ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА EpCAMxCD3 Download PDFInfo
- Publication number
- RU2012115480A RU2012115480A RU2012115480/15A RU2012115480A RU2012115480A RU 2012115480 A RU2012115480 A RU 2012115480A RU 2012115480/15 A RU2012115480/15 A RU 2012115480/15A RU 2012115480 A RU2012115480 A RU 2012115480A RU 2012115480 A RU2012115480 A RU 2012115480A
- Authority
- RU
- Russia
- Prior art keywords
- epcamxcd3
- bispecific
- antibody
- dose
- period
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract 15
- 102000004190 Enzymes Human genes 0.000 claims abstract 6
- 108090000790 Enzymes Proteins 0.000 claims abstract 6
- 210000002966 serum Anatomy 0.000 claims abstract 6
- 201000009030 Carcinoma Diseases 0.000 claims abstract 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims abstract 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- 230000002440 hepatic effect Effects 0.000 claims abstract 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract 3
- 238000001990 intravenous administration Methods 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24365109P | 2009-09-18 | 2009-09-18 | |
| US61/243,651 | 2009-09-18 | ||
| EP09170715 | 2009-09-18 | ||
| EP09170715.8 | 2009-09-18 | ||
| US34414710P | 2010-06-01 | 2010-06-01 | |
| US61/344,147 | 2010-06-01 | ||
| EP10164596.8 | 2010-06-01 | ||
| EP10164596 | 2010-06-01 | ||
| PCT/EP2010/063795 WO2011033105A1 (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012115480A true RU2012115480A (ru) | 2013-10-27 |
Family
ID=43127167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012115480/15A RU2012115480A (ru) | 2009-09-18 | 2010-09-20 | РЕЖИМ ДОЗИРОВАНИЯ ПРИ ВВЕДЕНИИ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА EpCAMxCD3 |
Country Status (15)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| AU2012350429A1 (en) | 2011-12-09 | 2013-07-11 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| PL2956477T5 (pl) | 2013-02-15 | 2024-05-27 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
| WO2014131694A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US11046763B2 (en) * | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| FI3377103T4 (fi) * | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
| RS63548B1 (sr) | 2016-02-01 | 2022-09-30 | Bioverativ Therapeutics Inc | Optimizovani geni faktora viii |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| AU2017233121B2 (en) | 2016-03-15 | 2023-12-21 | Itabmed (Hk) Limited | Multispecific Fab fusion proteins and use thereof |
| WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| BR112020004543A2 (pt) * | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| BR112022026127A2 (pt) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína |
| CN120818061A (zh) * | 2021-11-19 | 2025-10-21 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| KR20120125634A (ko) | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| DK1874821T3 (da) * | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
-
2010
- 2010-09-20 US US13/496,836 patent/US20120244161A1/en not_active Abandoned
- 2010-09-20 NZ NZ598601A patent/NZ598601A/en not_active IP Right Cessation
- 2010-09-20 RU RU2012115480/15A patent/RU2012115480A/ru not_active Application Discontinuation
- 2010-09-20 AU AU2010297258A patent/AU2010297258A1/en not_active Abandoned
- 2010-09-20 KR KR1020127007677A patent/KR20120083359A/ko not_active Withdrawn
- 2010-09-20 MX MX2012003175A patent/MX2012003175A/es not_active Application Discontinuation
- 2010-09-20 IN IN3172DEN2012 patent/IN2012DN03172A/en unknown
- 2010-09-20 SG SG10201405434VA patent/SG10201405434VA/en unknown
- 2010-09-20 CN CN2010800523771A patent/CN102711825A/zh active Pending
- 2010-09-20 SG SG2012016044A patent/SG179027A1/en unknown
- 2010-09-20 CA CA2774732A patent/CA2774732A1/en not_active Abandoned
- 2010-09-20 BR BR112012008345A patent/BR112012008345A2/pt not_active IP Right Cessation
- 2010-09-20 EP EP10755167A patent/EP2477653A1/en not_active Withdrawn
- 2010-09-20 WO PCT/EP2010/063795 patent/WO2011033105A1/en not_active Ceased
- 2010-09-20 JP JP2012529298A patent/JP2013505223A/ja active Pending
-
2012
- 2012-03-14 IL IL218637A patent/IL218637A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ598601A (en) | 2014-05-30 |
| IN2012DN03172A (cg-RX-API-DMAC7.html) | 2015-09-25 |
| BR112012008345A2 (pt) | 2016-08-09 |
| EP2477653A1 (en) | 2012-07-25 |
| CA2774732A1 (en) | 2011-03-24 |
| SG179027A1 (en) | 2012-04-27 |
| SG10201405434VA (en) | 2014-10-30 |
| IL218637A0 (en) | 2012-05-31 |
| WO2011033105A1 (en) | 2011-03-24 |
| AU2010297258A1 (en) | 2012-03-29 |
| CN102711825A (zh) | 2012-10-03 |
| MX2012003175A (es) | 2012-04-11 |
| JP2013505223A (ja) | 2013-02-14 |
| US20120244161A1 (en) | 2012-09-27 |
| KR20120083359A (ko) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012115480A (ru) | РЕЖИМ ДОЗИРОВАНИЯ ПРИ ВВЕДЕНИИ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА EpCAMxCD3 | |
| JP2013505223A5 (cg-RX-API-DMAC7.html) | ||
| Hanauer | Medical therapy for ulcerative colitis 2004 | |
| Asero et al. | 4 Usefulness of a Short Course of Oral Prednisone in Antihistamine-Resistant Chronic Urticaria: A Retrospective Analysis | |
| Toldo et al. | Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse | |
| Lin et al. | Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study | |
| Armuzzi et al. | Infliximab in the treatment of steroid-dependent ulcerative colitis | |
| Ciccarelli et al. | Psoriasis induced by anti-tumor necrosis factor alpha agents: a comprehensive review of the literature | |
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| NZ598661A (en) | Low frequency glatiramer acetate therapy | |
| US20080008716A1 (en) | Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease | |
| JP2019501886A5 (cg-RX-API-DMAC7.html) | ||
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| Chen et al. | Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support | |
| Mourad et al. | Adverse reactions to infliximab and the outcome of desensitization | |
| Spies et al. | Prednisone chronotherapy | |
| Wroblewski et al. | Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease | |
| RU2016108809A (ru) | Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба | |
| Ryu et al. | Infliximab for refractory oral ulcers | |
| Chen et al. | Drugs for the treatment of muscle atrophy | |
| Kawai et al. | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial | |
| Bascones-Martinez et al. | Oral manifestations of pemphigus vulgaris: clinical presentation, differential diagnosis and management | |
| Batticciotto et al. | AB0297 Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. | |
| US12194054B2 (en) | Application of Chidamide in combination with R-CHOP, and drug combination | |
| RU2537031C2 (ru) | Способ лечения цистита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150209 |